| Identification | Back Directory | [Name]
Mal-PEG2-VCP-Eribulin | [CAS]
2130869-18-8 | [Synonyms]
Eribulin+Linker
Mal-PEG2-VCP-Eribulin
Mal-PEG2-VC-PAB-Eribulin
L-Ornithinamide, N-[3-[2-[2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)ethoxy]ethoxy]-1-oxopropyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(2S)-2-hydroxy-3-[(2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-octacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-5-oxo-11,15:18,21:24,2... | [Molecular Formula]
C70H99N7O21 | [MDL Number]
MFCD32197298 | [MOL File]
2130869-18-8.mol | [Molecular Weight]
1374.59 |
| Hazard Information | Back Directory | [Uses]
Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates[1][2][3]. | [IC 50]
Traditional Cytotoxic Agents | [References]
[1] Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.
[2] Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505. DOI:10.1158/0008-5472.CAN-10-1874
[3] Watanabe K, et al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4;10(2):161-174. DOI:10.18632/oncotarget.26536 |
|
|